A low starting dose is the norm, not the exception
Every GLP-1 peptide used for weight management starts well below its effective range. Semaglutide starts at 0.25mg against a maintenance range up to 2.4mg. Tirzepatide starts at 2.5mg against a maintenance range up to 15mg. Retatrutide’s published trial schedules start at 2mg against arms that went as high as 12mg. In every case, the starting dose exists to introduce the drug’s effect gradually, not because it’s expected to do much on its own.
Why the starting dose barely “works”
At the starting dose, appetite and digestion changes are usually mild. That’s intentional. The goal is to let the gut adjust to the drug’s presence before the dose increases to a level that produces a stronger effect.
What determines how low the start is
Receptor activity matters here. A drug that activates more receptors, or activates them more strongly, tends to start lower relative to its own maintenance range, since the side-effect risk from starting too high is greater. This is part of why retatrutide’s triple-receptor action gets more attention around titration pace than single-receptor drugs.
How the starting dose is chosen for a specific person
Body weight, prior GLP-1 experience, and how sensitive someone is to nausea all factor into real-world starting choices, though the published trial dose is the only figure with actual data behind it. Someone who’s already used a related peptide sometimes starts slightly higher; this varies by individual circumstance rather than following one fixed rule.
The takeaway
A low starting dose isn’t a sign the drug is weak, and a fast climb off that starting dose isn’t a shortcut to better results. It’s a deliberate design choice that shows up across every GLP-1 peptide on the market.